Table 3.
Clinical features according to severity of COVID-19 vaccine-related headache.
| Mild vaccine related headachen = 126 | Moderate vaccine related headachen = 370 | Severe vaccine related headachen = 60 | p* (1 vs. 3) | p* (2 vs. 3) | |
|---|---|---|---|---|---|
| Vaccine-related headache during ≥3 days, n (%) | 19 (15.1) | 105 (28.4) | 20 (33.3) | 0.007 | 0.43 |
| Vaccine-related headache during <3 days, n (%) | 107 (84.9) | 265 (71.6) | 40 (66.6) | ||
| Associated fever, n (%) | 13 (10.3) | 38 (10.3) | 3 (5) | 0.59 | 0.24 |
| Pre-existing primary headaches, n (%) | 70 (55.5) | 261 (70.5) | 46 (76.7) | 0.005 | 0.33 |
| Definite migraine, n (%) | 16 (12.7) | 92 (24.9) | 23 (38.3) | <0.001 | 0.029 |
| Duration between COVID-19 and vaccination, months, median (IQR)** | 5.5 (3–9) | 3 (2.25–6.5) | 4 (2–5) | 0.41 | 0.89 |
Note: Numbers in bold are statistically significant values.*Pearson Chi-Square, Fisher’s Exact test or Mann–Whitney U.
IQR: interquartile range (Q1–Q3).
**18, 28 and three participants reported mild, moderate and severe vaccine related headache, respectively.